Diabetes-induced vascular dysfunction involves arginase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 1, 2012, Pages

  Romero, Maritza J ^a   Iddings, Jennifer A ^a   Platt, Daniel H ^a   Irfan Ali, M ^b   Cederbaum, Stephen D ^c   Stepp, David W ^b   Caldwell, Ruth B ^b   Caldwell, Robert W ^a  

^a Department of Pharmacology and Toxicology ^*  (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibrosis; Oxidative stress; Vascular stiffness

Indexed keywords

ACETYLCHOLINE; ARGINASE 1; ARGINASE 2; HYDROLASE; HYDROXYPROLINE; LIPID HYDROPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL STIFFNESS; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROSIS; GENE DELETION; GENOTYPE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALS; AORTA; ARGINASE; ARTERIES; CAROTID ARTERIES; COMPLIANCE; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HYDROGEN PEROXIDE; HYDROXYPROLINE; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SUPEROXIDES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84255192664     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00774.2011     Document Type: Article

References (36)

1. Bagnost T, Ma L, da Silva RF, Rezakhaniha R, Houdayer C, Stergio-pulos N, Andre C, Guillaume Y, Berthelot A, Demougeot C. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 87: 569-577, 2010.
2. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 300: H777-H783, 2011.
3. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15: 1101-1108, 2002.
4. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 283: 923-927, 2001.
5. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatzi-antoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 100: 1901-1908, 1999.
6. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625, 2005.
7. Caldwell RB, Zhang W, Romero MJ, Caldwell RW. Vascular dysfunction in retinopathy-an emerging role for arginase. Brain Res Bull 81: 303-309, 2010.
8. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol Genet Metab 81, Suppl 1: S38-S44, 2004.
9. Chang KS, Stevens WC. Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta. Br J Pharmacol 107: 983-990, 1992.
10. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procol-lagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291: H1738-H1745, 2006.
11. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 287: L60-L68, 2004.
12. Cohen RA, Tong X. Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol 55: 308-316, 2010.
13. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 174: 231-235, 1994.
14. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82: 9-20, 2009.
15. Goodarzi MT, Navidi AA, Rezaei M, Babahmadi-Rezaei H. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 24: 72-76.
16. Gronros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 300: H1174-H1181, 2011.
17. Huynh NN, Andrews KL, Head GA, Khong SM, Mayorov DN, Murphy AJ, Lambert G, Kiriazis H, Xu Q, Du XJ, Chin-Dusting JP. Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. Hypertension 54: 294-301, 2009.
18. Jiang M, Jia L, Jiang W, Hu X, Zhou H, Gao X, Lu Z, Zhang Z. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun 309: 196-200, 2003.
19. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 19: 247-252, 2009.
20. Kinlay S, Creager MA, Fukumoto M, Hikita H, Fang JC, Selwyn AP, Ganz P. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 38: 1049-1053, 2001.
21. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/en-dothelial nitric oxide synthase double-knockout mice. Circulation 104: 448-454, 2001.
22. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol 276: H1943-H1950, 1999.
23. Li H, Meininger CJ, Hawker JR, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280: E75-E82, 2001.
24. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 884-899, 1977.
25. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102, 2008.
26. Shatanawi A, Romero M, Iddings J, Chandra S, Umapathy N, Verin A, Caldwell R, Caldwell R. Angiotensin II increases arginase activity and expression through RhoA/Rho kinase and p38 mitogen-activated protein kinase (MAPK) pathways. Am J Physiol Cell Physiol 300: C1181-C1192, 2011.
27. Shi O, Morris SM, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 21: 811-813, 2001.
28. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 11: 61-74, 2010.
29. Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, Veeraveedu PT, Konishi T, Zhang S, Muslin AJ, Kodama M, Aizawa Y. Dominant-negative p38a mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol 297: H911-H919, 2009.
30. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Car-neiro Z, Inscho E, Webb RC, Caldwell RB, Caldwell RW. p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angio-tensin-II treated mice. J Sex Med 7: 3857-3867, 2010.
31. van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, Tschope C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 103: 319-327, 2008.
32. Wusteman MC, Simmonds J, Vaughan D, Pegg DE. Vitrification of rabbit tissues with propylene glycol and trehalose. Cryobiology 56: 62-71, 2008.
33. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 32: 958-964, 1998.
34. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 15: 1264-1266, 2001.
35. Zhang C, Wu J, Xu X, Potter BJ, Gao X. Direct relationship between levels of TNF-a expression and endothelial dysfunction in reperfusion injury. Basic Res Cardiol 105: 453-464, 2010.
36. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25: 932-943, 2005.